Shifting Standards in Frontline HER2+ Metastatic Breast Cancer Management
New clinical trial data released in 2026 indicate that frontline treatment strategies for HER2-positive (HER2+) metastatic breast cancer (MBC) are moving beyond the long-standing taxane, trastuzumab, and pertuzumab (THP) standard. According to findings from the phase 3 DESTINY-Breast09 trial, the combination of trastuzumab deruxtecan (T-DXd) and pertuzumab offers significantly improved progression-free survival (PFS) compared to the traditional THP regimen. Furthermore, emerging maintenance strategies incorporating CDK4/6 inhibitors or tyrosine kinase inhibitors are demonstrating efficacy in prolonging disease control for patients with hormone receptor–positive (HR+) disease and those transitioning from induction therapy.
How does T-DXd plus pertuzumab compare to the CLEOPATRA standard?
For over a decade, the CLEOPATRA regimen—a taxane backbone paired with trastuzumab and pertuzumab—served as the primary frontline therapy for HER2+ MBC. Data published in the New England Journal of Medicine (2026) from the DESTINY-Breast09 trial challenge this benchmark.
In the study, 1,157 patients were randomized to receive either T-DXd plus pertuzumab or the standard THP. Researchers reported a median PFS of 40.7 months for the T-DXd combination, compared with 26.9 months for the THP control arm (hazard ratio, 0.56). While the new regimen shows clear superiority in survival metrics, clinicians must monitor for specific adverse events. The study noted adjudicated drug-related interstitial lung disease or pneumonitis in 12.1% of patients receiving the T-DXd combination, compared to 1.0% in the THP group.
Can CDK4/6 inhibitors improve maintenance therapy outcomes?
The addition of a CDK4/6 inhibitor to maintenance endocrine therapy (ET) and HER2-targeted agents may prevent progression in patients with HR+/HER2+ MBC. The phase 3 PATINA trial, as reported in the New England Journal of Medicine (2026), evaluated the efficacy of adding palbociclib to maintenance therapy following induction chemotherapy.
Patients who received palbociclib in addition to ET and HER2-targeted therapy experienced a median PFS of 44.3 months, versus 29.1 months for those receiving maintenance therapy alone. Notably, secondary analysis suggested a potential neuroprotective effect; the cumulative risk of central nervous system progression or death at 36 months was 13.0% in the palbociclib arm compared to 19.2% in the control group.
Pro Tip: When managing HR+/HER2+ patients, clinicians should consider the potential for CDK4/6 inhibitors to delay CNS progression, as suggested by the PATINA trial data, even in the absence of baseline CNS symptoms.
What is the role of tucatinib in maintenance regimens?
The HER2CLIMB-05 trial, published in the Journal of Clinical Oncology (2025), established the benefit of adding the tyrosine kinase inhibitor tucatinib to a maintenance regimen of trastuzumab and pertuzumab. Among 654 patients who had not progressed after initial induction therapy, those receiving tucatinib maintenance achieved a median PFS of 24.9 months, significantly outperforming the 16.3 months seen with trastuzumab and pertuzumab alone.
The benefit was observed across both HR-positive and HR-negative subgroups, though researchers noted a higher hazard ratio improvement in the HR-negative population (0.554) compared to the HR-positive subset (0.725). The most frequently reported adverse events in the tucatinib arm included diarrhea (72.7%) and elevated liver enzymes.
Frequently Asked Questions
What is the current standard of care for frontline HER2+ MBC?
While the CLEOPATRA regimen (THP) has been the historical standard, 2026 data from DESTINY-Breast09 suggest the T-DXd plus pertuzumab combination may offer superior progression-free survival.
Does adding palbociclib to maintenance therapy affect CNS progression?
Yes, according to the PATINA trial, the inclusion of palbociclib in maintenance therapy for HR+/HER2+ MBC may help reduce the cumulative risk of CNS progression or death.
How does tucatinib impact maintenance therapy for HER2+ MBC?
The HER2CLIMB-05 study demonstrated that adding tucatinib to trastuzumab and pertuzumab maintenance significantly extends PFS compared to using the antibodies alone.
What are the most common side effects associated with T-DXd plus pertuzumab?
Common grade 3 or higher treatment-related adverse events include neutropenia (23.9%), hypokalemia (10.2%), and anemia (8.4%). Clinicians should also screen for drug-related interstitial lung disease.
***
Are you a healthcare professional looking to integrate these findings into your clinical practice? Explore the full range of educational resources and claim your continuing medical education credits at the [Physicians’ Education Resource® portal](https://www.gotoper.com/mbcc26her2maintenance-activity).
